Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats.
1. Angiotensin converting enzyme (ACE)-inhibitors have been demonstrated to be effective in the treatment of cardiac hypertrophy when used in antihypertensive doses. The aim of our one year study with an ACE-inhibitor in rats was to separate local cardiac effects produced by a non-antihypertensive dose from those on systemic blood pressure when an antihypertensive dose was used. 2. Rats made hypertensive by aortic banding were subjected to chronic oral treatment for one year with an antihypertensive dose of the ACE inhibitor, ramipril 1 mg kg-1 daily, (RA 1 mg) or received a low dose of 10 micrograms kg-1 daily (RA 10 micrograms) which did not affect high blood pressure. 3. Chronic treatment with the ACE-inhibitor prevented left ventricular hypertrophy in the antihypertensive rats as did the low dose which had no effects on blood pressure. Similar effects were observed on myocardial fibrosis. Plasma ACE activity was inhibited in the RA 1 mg but not in the RA 10 micrograms group although conversion of angiotensin (Ang) I to Ang II in isolated aortic strips was suppressed in both treated groups. Plasma catecholamines were increased in the untreated control group, but treatment with either dose of ramipril normalized the values. The myocardial phosphocreatine to ATP ratio (an indicator of the energy state in the heart) was reduced in the vehicle control group whereas the hearts from treated animals showed a normal ratio comparable to hearts from sham-operated animals. 4. After one year, five animals were separated from each group, treatment withdrawn, and housed for additional six months. In the RA 1 mg group, blood pressure did not reach the value of the control vehicle group and surprisingly, left ventricular hypertrophy and myocardial fibrosis did not recur in animals during withdrawal of treatment.5. These data show that long term ACE inhibitor treatment with ramipril in antihypertensive and non-antihypertensive doses prevented cardiac hypertrophy and myocardial fibrosis. This protective effect was still present after 6 months treatment withdrawal.
Linz
W
W
Department of Pharmacology, Hoechst AG, Frankfurt/Main, Germany.
Schaper
J
J
Wiemer
G
G
Albus
U
U
Schölkens
B A
BA
D000255:Adenosine Triphosphate / Q000378:metabolism; D000809:Angiotensins / Q000378:metabolism; D000818:Animals; D001013:Aorta, Thoracic / Q000737:chemistry; D001794:Blood Pressure / Q000187:drug effects*; D006332:Cardiomegaly / Q000517:prevention & control*; D002395:Catecholamines / Q000097:blood; D006152:Cyclic GMP / Q000378:metabolism; D004719:Endomyocardial Fibrosis / Q000517:prevention & control*; D006973:Hypertension / Q000188:drug therapy; D008297:Male; D009206:Myocardium / Q000378:metabolism; D007703:Peptidyl-Dipeptidase A / Q000032:analysis / Q000097:blood*; D010725:Phosphocreatine / Q000378:metabolism; D011863:Radioimmunoassay; D017257:Ramipril / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D011918:Rats, Inbred SHR; D017207:Rats, Sprague-Dawley
D000809:Angiotensins; D002395:Catecholamines; D010725:Phosphocreatine; D000255:Adenosine Triphosphate; D007703:Peptidyl-Dipeptidase A; D006152:Cyclic GMP; D017257:Ramipril